Status:
COMPLETED
Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Solid Tumors
Lymphoma, Non-Hodgkin
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Part 1 and Part 2 of this trial will evaluate the safety, tolerability, maximum administered dose, and dose limiting toxicity of SCH 727965 administered every 3 weeks as a 2 hour intravenous (IV) infu...
Eligibility Criteria
Inclusion
- Age \>=18 years, either sex, any race.
- Subjects must have histologically proven solid tumors, non-Hodgkin's lymphoma, or multiple myeloma.
- There must be no known standard therapy, or disease must be refractory to standard therapy.
- Eastern Cooperative Oncology Group performance status of 0, 1, or 2.
- Adequate hematologic, renal, and hepatic organ function and laboratory parameters.
Exclusion
- Symptomatic brain metastases or primary central nervous system malignancy.
- Previous radiation therapy to \>25% of the total bone marrow.
- Previous treatment with SCH 727965.
- Known HIV infection.
Key Trial Info
Start Date :
October 11 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 22 2010
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT00871910
Start Date
October 11 2006
End Date
February 22 2010
Last Update
October 23 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.